



# Ravenscroft Investment Fund Offshore

## Global Blue Chip Fund

**INVESTMENT MANAGERS: RAVENSCROFT INVESTMENT MANAGEMENT LIMITED**

### THEME WEIGHTINGS



**33% Technology & Innovation**

- Information Technology
- Engineering & Industrials

**31% Healthcare**

- Pharmaceuticals
- Medical Devices

**30% Global Brands**

- Consumer Staples
- Consumer Discretionary

**6% Cash & Equivalents**

### FUND AIMS AND OBJECTIVES

The Global Blue Chip Fund's main objective is to generate long-term capital growth from a focused portfolio of large global businesses, which are listed on recognised stock exchanges in developed countries. It is actively managed and not constrained by a benchmark.

Ravenscroft Global Blue Chip is a sub-fund of the Ravenscroft Investment Fund Offshore; an open-ended, multi-class Unit Trust authorised as a Class B Scheme by the Guernsey Financial Services Commission.

### PERFORMANCE CHART



### FUND SIZE: £109.1M

Past performance is not a reliable indicator of future results.

### FUND MANAGER COMMENTARY

Your Fund returned 4.9% during the month bringing the year-to-date return to 2.4%. By comparison, the MSCI World Index returned 4.8% during the month driven by the strength of the Utilities +9.3%, Consumer Staples +8.0% and Industrials +7.5% sectors. Year-to-date the index has returned 4%.

BMW was March's top performer, returning 18.8% during the month and contributing 0.6% to the overall performance. The market welcomed BMW's "new" battery electric vehicle ("BEV") strategy following the announcement at its annual conference that at least 50% of BMW's global sales will be fully electric by 2030. We would argue that this was not a new revelation but rather a continuation of the company's pre-existing strategy centred around a flexible approach that allows BMW's propulsion mix to be led by consumer demand.

Elsewhere, Henkel and 3M both posted strong performance (up 12.9% and 11.5% respectively). Oracle also provided double-digit returns (+10.2%) and we were encouraged by the announcement that the company would double its rate of capital expenditure - a clear indication of the future demand the company is expecting for its services.

Illumina (down 11.4% and detracting 0.3%) was the worst performer during March. Its shares fell significantly on the news that the Federal Trade Commission ("FTC") had filed to block Illumina's \$7.1 billion acquisition of Grail. The Successful acquisition did not form part of our original investment rationale but we couldn't help but feel slightly bemused by the fact that the FTC found issue on anti-competition grounds. Grail had only been spun out of Illumina 5 years earlier and its technology had

been honed under its watch. There were only three other detractors, Alnylam (down 3.4%), Disney (down 1.1%) and Nike (down 0.1%).

We made a number of changes to the Fund during the month. First, we exited the remainder of the strategy's allocation to Nestle on valuation grounds. We used the proceeds to top up the BMW position which continues to look compelling. We also added marginally to Colgate and Unilever, both of which had retraced from their recent highs, over input inflation fears. Finally, we took the broader rotation out of the technology sector as an opportunity to add to the strategy's Microsoft allocation on a rare period of weakness - increasing the holding from a 2.5% to 3% position.

The value of the Fund may go down as well as up - you may get back less than you invested.

### 3 YEAR PERFORMANCE BREAKDOWN

	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC	YTD
2019	0.67%	3.02%	4.61%	2.44%	-0.18%	5.51%	4.09%	0.19%	-0.36%	-3.38%	2.55%	0.11%	20.64%
2020	0.43%	-5.04%	-3.44%	6.53%	5.27%	0.28%	-2.87%	3.12%	1.01%	-4.42%	7.34%	1.82%	9.46%
2021	-1.61%	-0.81%	4.93%										2.40%

Past performance is not a guide to future performance and may not be repeated. Source: Ravenscroft Investments Management Limited, collated 13/04//2021

### PERFORMANCE ANALYSIS (Inception date: 1 July 2014)

1 Year	3 Year	5 Year	Inception	Annual Compound Growth Rate
21.70%	49.45%	61.30%	95.86%	10.47%

All figures are based on the Fund's distribution class, inclusive of fees and assuming all dividends are reinvested.

### BLUE CHIP PORTFOLIO

FUND	WEIGHTING
<b>Global Brands</b>	
BMW	4.2%
Colgate-Palmolive	2.6%
Diageo	3.3%
Henkel	4.1%
L'Oreal	3.0%
LVMH	3.1%
Nike	1.7%
PepsiCo	2.6%
Richmont	3.2%
Unilever	3.5%
Walt Disney	2.9%
	<b>34.2%</b>
<b>Technology &amp; Innovation</b>	
3M	4.3%
Alphabet	3.1%
Honeywell	4.0%
Intel	3.8%
Microsoft	3.0%
Oracle	4.7%
Relx	2.8%
Visa	2.8%
	<b>28.5%</b>
<b>Healthcare</b>	
Alnylam Pharmaceuticals	0.9%
Edward Lifesciences	2.1%
Illumina	2.3%
Johnson & Johnson	3.8%
Medtronic	3.9%
Novartis	4.4%
Regeneron Pharmaceuticals	2.0%
Roche	4.4%
Sanofi	4.4%
Waters	2.6%
	<b>30.8%</b>
<b>Cash &amp; Equivalents</b>	
Cash	3.8%
JPMorgan Sterling Liquidity	2.7%
	<b>6.5%</b>

### DIVIDEND HISTORY

Historic Yield 1.2%

#### Semi-Annual Dividend Announcement

Ex Date:	1st April 2020
Rate per O unit:	DIST: £0.99 ACC: £1.09
Rate per I unit:	DIST: £0.97 ACC: £1.07
Ex Date:	1st October 2020
Rate per O unit:	DIST: £1.14 ACC: £1.25
Rate per I unit:	DIST: £1.12 ACC: £1.24

Dividends are paid a calendar month after each half year  
Please note that income levels are not guaranteed and can fluctuate.

### KEY POINTS

#### Dealing Frequency:

Daily (cut-off 5pm GMT one Business Day prior to Dealing Day)

#### Settlement Period: T+4

Annual Management Fee: 'O' Class - 0.75%  
'I' Class - 1%

#### Minimum Investment: £5,000.00

Sedol / ISIN: 'O' Class ACC: BN707P7 / GGO0BN707P73  
DIST: BN707Q8 / GGO0BN707Q80  
'I' Class ACC: BN707M4 / GGO0BN707M43  
DIST: BN707N5 / GGO0BN707N59

#### Trustees: BNP Paribas Securities Services S.C.A. Guernsey Branch

A copy of the Trust Instrument and Scheme Particulars can be obtained by contacting the Administrator:

Praxis Fund Services Limited

T: +44 1481 737600

E: Ravenscroft@PraxisIFM.com

For further information from the Manager, please use the below details:

**PO Box 222, 20 New Street, St Peter Port, Guernsey, GY1 4JG**

**t +44 (0)1481 729100 w [ravenscroftgroup.com](http://ravenscroftgroup.com)**

Ravenscroft is a trading name of Ravenscroft Investment Management Limited ("RIML"), which is licensed and regulated by the Guernsey Financial Services Commission to conduct investment business. For all Ravenscroft connected entities, please refer to [www.ravenscroftgroup.com/disclaimer](http://www.ravenscroftgroup.com/disclaimer). All calls will be recorded and monitored for training and security purposes. This is not an offer or solicitation with respect to the purchase or sale of any security. This fact sheet is intended only to facilitate your discussions with Ravenscroft as to the opportunities available to our clients. The given material is subject to change and, although based upon information which we consider reliable, it is not guaranteed as to accuracy or completeness and it should not be relied upon as such. The material is not intended to be used as a general guide to investing, or as a source of any specific investment recommendations, and makes no implied or express recommendations concerning the manner in which any client's account should or would be handled, as appropriate investment strategies depend upon client's investment objectives. This material does not constitute an offer or solicitation to any person in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it would be unlawful to make such offer or solicitation. It is the responsibility of any person or persons in possession of this material to inform themselves of and to observe all applicable laws and regulations of any relevant jurisdiction. Prospective investors should inform themselves and take appropriate advice as to any applicable legal requirements and any applicable taxation and exchange control regulations in the countries of their citizenship, residence or domicile which might be relevant to the subscription, purchase, holding, exchange, redemption or disposal of any investments. Ravenscroft does not provide tax advice to its clients and all investors are strongly advised to consult with their tax advisors regarding any potential investment. Opinions expressed are our current opinions as of the date appearing on this material only. Any historical price(s) or value(s) are also only as of the date indicated. While we endeavour to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Certain transactions, including those involving futures, options and high yield securities and investments in emerging markets may give rise to substantial risk and may not be suitable for all investors. Foreign currency denominated investments are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment; such investments are also subject to the possible imposition of exchange control regulations or other laws or restrictions applicable to such investments. Investments referred to in this material are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. Investors should consider whether an investment is suitable for their particular circumstances and seek advice from Ravenscroft. The price and value of the investments referred to in this material and the income from them may go down as well as up and investors may realise losses on any investments. Past performance is not a guide to future performance. Future returns are not guaranteed and a loss of principal may occur.